# TYZAVAN - (500MG/100ML, 1000MG/200ML, 1500MG/300ML, 2000MG/400ML, 750MG/150ML, 1250MG/250ML, 1750MG/350ML ; Solution)

| | | | |
|---|---|---|---|
| **Generic Name** | VANCOMYCIN HYDROCHLORIDE | **Innovator** | Hikma |
| **Dosage** | 500MG/100ML, 1000MG/200ML, 1500MG/300ML, 2000MG/400ML, 750MG/150ML, 1250MG/250ML, 1750MG/350ML ; Solution | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | None |
| **Other ANDA developers** | More Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | Vancomycin Injection is a glycopeptide antibacterial indicated in adult and pediatric patients (1 month and older) for the treatment of: • Septicemia • Infective Endocarditis • Skin and Skin Structure Infections • Bone Infections • Lower Respiratory Tract Infections | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.